Document is current
Any future updates will be listed below
-
Authors
Tasegian, Anna https://orcid.org/0000-0001-6122-265X
Dikovskaya, Dina https://orcid.org/0000-0003-3161-3072
Scott, Molly M. https://orcid.org/0000-0002-6329-1816
Chawla, Amanpreet Singh https://orcid.org/0000-0001-5265-3431
Pemberton, Rebecca
Helps, Thomas
Meus, Tosca
McLean, Mairi H. https://orcid.org/0000-0002-7443-2653
Swamy, Mahima https://orcid.org/0000-0003-3977-3425
-
Funding
Funding for this research was provided by:
Wellcome Trust (206246/Z/17/A)
Interline Therapeutics
Tenovus Scotland
RCUK | Medical Research Council
- License Information
-
More Information
Article History
Received: 15 January 2024
Accepted: 6 September 2024
First Online: 8 October 2024
Competing interests
: M.S. receives research funding from AstraZeneca and Interline Therapeutics. M.H.M. receives research funding from beLAB1407 (Evotec and Bristol Myers Squibb). A.T. is currently an employee of Amphista Therapeutics. The other authors declare no competing interests.
